News Author: HT Staff Publish date: September 7, 2016
of nasal spray
Bevacizumab nasal spray is no more effective than a placebo for reducing epistaxis caused by hereditary hemorrhagic telangiectasia (...
News Author: HT Staff Publish date: September 7, 2016
Photo courtesy of St.
News Author: HT Staff Publish date: September 6, 2016
Photo by Chad McNeeley
New research suggests hematopoietic stem cell transplant (HSCT) may increase the molecular age of peripheral blood T cells.
...
News Author: HT Staff Publish date: September 5, 2016
Photo courtesy of the CDC
Cancer patients have a heightened risk of injuries 16 weeks before and after their diagnosis, according to a large study....
News Author: HT Staff Publish date: September 4, 2016
Image by Volker Brinkmann
Developing blood cells are caught in a tug of war between competing gene regulatory networks before finally deciding what...
News Author: HT Staff Publish date: September 3, 2016
Photo by Sage Ross
ROME—A subanalysis of the PRODIGY study suggests a longer duration of dual antiplatelet therapy (DAPT) improves outcomes after p...
News Author: HT Staff Publish date: September 2, 2016
and solution for infusion
Photo courtesy of Amgen
The US Food and Drug Administration (FDA) has granted accelerated approval for blinatumomab (Bli...
News Author: HT Staff Publish date: September 2, 2016
Image courtesy of
Medical College of Georgia
ROME—A new study suggests the YEARS algorithm may provide a simple method for ruling out pulmonary em...
News Author: HT Staff Publish date: September 2, 2016
ROME—The novel oral anticoagulant edoxaban is a feasible treatment option for patients with atrial fibrillation (AF) who need anticoagulation before c...
News Author: HT Staff Publish date: September 2, 2016
Photo by Linda Bartlett
The European Commission has granted orphan drug designation to ALXN1007 for the treatment of graft-versus-host disease (GVH...
News Author: HT Staff Publish date: September 1, 2016
Photo courtesy of GSK
The US Food and Drug Administration (FDA) has approved the use of ofatumumab (Arzerra®) in combination with fludarabine and c...
News Author: HT Staff Publish date: September 1, 2016
ROME—Preliminary results from the ANNEXA-4 study suggest that andexanet alfa, an investigational antidote to factor Xa inhibitors, can be effective in...
News Author: HT Staff Publish date: September 1, 2016
Photo courtesy of AstraZeneca
ROME—The antiplatelet drugs prasugrel and ticagrelor produce similar early results in patients with acute myocardial ...
News Author: HT Staff Publish date: September 1, 2016
Photo by Daniel Gay
Results of preclinical research may explain why people with blood type O often get more severely ill from cholera than people w...
News Author: HT Staff Publish date: August 31, 2016
of women in a family
ROME—According to researchers, a clinical decision rule can identify women who, after their first unprovoked venous thromboemb...
